Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization

Lahitte, G. Ducos de; Cohen, Salomon Y.; Gaudric, Alain

doi:10.1016/j.ajo.2004.06.010

Cited by 47 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De Lahitte et al [43] analyzed the effect of PDT in bilateral acquired parafoveal telangiectasias without CNV in 2 women. The eye with lesser VA was treated.…”

Section: Other Pdt Applications In Ophthalmologymentioning

confidence: 99%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

et al. 2007

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597–599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these ‘case series’ and ‘individual case control studies’ have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).

show abstract

“…De Lahitte et al [43] analyzed the effect of PDT in bilateral acquired parafoveal telangiectasias without CNV in 2 women. The eye with lesser VA was treated.…”

Section: Other Pdt Applications In Ophthalmologymentioning

confidence: 99%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

et al. 2007

View full text Add to dashboard Cite

show abstract

“…An improvement of visual acuity could be observed in 1 of those 2 subjects treated with standard-fluence PDT [23]. Histological studies in animal models and humans have demonstrated that PDT leads to endothelial changes with consequent reduction of vascular permeability [34,35].…”

Section: Discussionmentioning

confidence: 99%

“…PDT has been proven to be efficacious in nonneovascular macular diseases with edema such as chronic central serous chorioretinopathy [23,34]. …”

Section: Discussionmentioning

confidence: 99%

“…For standard-fluence photodynamic therapy (PDT) there are only 2 reported cases in literature and none for reduced-fluence PDT. An improvement of visual acuity could be observed in 1 of these 2 subjects [23]. Case reports and a few small series have not shown convincing efficacy of intravitreal triamcinolone or grid laser in improving vision [24,25,26].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2

Zehetner¹,

Haas²,

B³

et al. 2013

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To report the efficacy of reduced-fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2. Methods: Noncomparative, interventional, retrospective case series; 5 eyes of 4 patients were studied. Patients were treated with reduced-fluence PDT and intravitreal ranibizumab within 24 h. After initial treatment, follow-up was at least 12 months in all patients. Results: At baseline median logMAR (logarithm of the minimal angle of resolution) best-corrected visual acuity (BCVA) was 1.0 (range, 1.0-0.3). At 3 months of follow-up vision increased in 3 out of 5 eyes and median BCVA was 0.4 (range, 1.0-0.2). The gain of BCVA ranged from 6 lines to 1 line. Visual acuity remained stable in the other 2 study eyes. No eyes lost vision at 3 months of follow-up. At 12 months of follow-up median logMAR BCVA was 0.7 (range, 1.3-0.3). Two eyes had maintained their gain in BCVA compared to baseline. Two eyes lost vision compared to baseline and 1 eye showed unchanged visual acuity at 12 months of follow-up. Conclusion: A combination therapy with reduced-fluence PDT and intravitreal ranibizumab might be a valuable treatment option for eyes with progressive vision loss due to nonproliferative MacTel type 2.

show abstract

“…Verteporfin PDT was also tried in patients with nonproliferative IMT II in an attempt to reduce the permeability of the telangiectatic vessels [60]. However, PDT improved neither vision nor the macular edema and appeared therefore not effective.…”

Section: Retinal Telangiectasiasmentioning

confidence: 99%

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

et al. 2012

View full text Add to dashboard Cite

Primitive retinal vascular abnormalities are benign conditions of the retinal circulation that comprise vascular tumors and telangiectasias. The principal vascular tumors of the retina include retinal capillary hemangioma, cavernous hemangioma of the retina, racemose hemangiomatosis of the retina and retinal vasoproliferative tumor, while primary retinal telangiectasias include Coats’ disease, Leber’s miliary aneurysms and idiopathic juxtafoveal telangiectasias. In most cases, these alterations result in significant visual impairment due to exudation determined by the structural abnormalities of the retinal vasculature. The aim of this review is to assess the different clinical and diagnostic features of the single pathological entities and to discuss the available treatment modalities including the onset of intravitreal antivascular endothelial growth factor therapy.

show abstract

Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization

Cited by 47 publications

References 5 publications

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

Contact Info

Product

Resources

About